Published in J Virol Methods on October 06, 2017
Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol (2004) 10.60
Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques (2006) 5.91
Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med (2009) 5.47
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol (1994) 4.67
High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One (2011) 3.90
Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol (2004) 3.42
Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A (2005) 3.34
En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol (2010) 2.90
A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods (1989) 2.53
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92
Cytomegalovirus cell tropism. Curr Top Microbiol Immunol (2008) 1.89
Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol (2012) 1.50
Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol (2008) 1.45
Skipping the co-expression problem: the new 2A "CHYSEL" technology. Genet Vaccines Ther (2004) 1.43
Complex correlates of protection after vaccination. Clin Infect Dis (2013) 1.36
Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A (2002) 1.24
Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS One (2008) 1.23
Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci U S A (2015) 1.17
Human cytomegalovirus entry into cells. Curr Opin Virol (2012) 1.12
Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol (1993) 1.10
A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol (2012) 1.09
Cytomegalovirus vaccine development. Curr Top Microbiol Immunol (2008) 1.08
A myeloid progenitor cell line capable of supporting human cytomegalovirus latency and reactivation, resulting in infectious progeny. J Virol (2012) 1.07
New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev Vaccines (2009) 1.07
Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine (2013) 1.06
[Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus]. Zentralbl Veterinarmed B (1966) 1.05
Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol (2009) 1.04
Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad Sci U S A (2014) 0.99
Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine (2014) 0.97
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog (2014) 0.97
Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine (2012) 0.93
Epstein-barr virus vaccines. Clin Transl Immunology (2015) 0.88
Vaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection. J Virol (2015) 0.87
Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies. PLoS Pathog (2015) 0.87
gH/gL supercomplexes at early stages of herpesvirus entry. Curr Opin Virol (2016) 0.81
Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. Nat Microbiol (2016) 0.80
Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus. J Virol (2017) 0.79
Status of vaccine research and development of vaccines for herpes simplex virus. Vaccine (2016) 0.77
Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. JCI Insight (2017) 0.76
Cytomegalovirus vaccines under clinical development. J Virus Erad (2016) 0.76
The COMPLEXity in herpesvirus entry. Curr Opin Virol (2017) 0.75
Structural basis for potent antibody-mediated neutralization of human cytomegalovirus. Sci Immunol (2017) 0.75